Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
Zejula (niraparib) shows durable and sustained long-term progression-free survival benefit in the PRIMA study of first-line platinum-responsive advanced ovarian cancer
GSK today announced long-term data from the phase III PRIMA study
GSK announces update on US FDA regulatory review of daprodustat in anaemia of chronic kidney disease
GSK today announced that the US FDA will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review daprodustat
WHO grants prequalification to GSK’s Mosquirix – the first and only approved malaria vaccine
An important step for rolling out the vaccine to children living in regions with moderate to high transmission.
GSK to highlight the latest advances in cancer research from across its portfolio and pipeline at ESMO
GSK will present new findings from across its diverse oncology portfolio and pipeline at the congress.
GSK Board changes
Elizabeth (Liz) McKee Anderson to join the Board as Non-Executive Director
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial
Statement: Zantac (ranitidine) U.S. litigation
Statement regarding U.S. Zantac (ranitidine) litigation
GSK completes acquisition of Affinivax, Inc.
GSK today announced it has completed the acquisition of Affinivax, Inc, a clinical-stage biopharmaceutical company based in Cambridge.
Statement: Zantac (ranitidine) litigation
Response to recent speculative commentary regarding U.S. Zantac litigation
GSK Announces Offer to Repurchase Exchangeable Senior Notes Due 2023
GSK Finance (No.3) plc, is offering to repurchase for cash any and all of its outstanding Exchangeable Senior Notes due 2023.
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine
Selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP
ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets
Findings show that cabotegravir LA for PrEP continued to demonstrate superior efficacy in the prevention of new HIV infections among women
GSK signs agreement to support pandemic preparedness in Europe
GSK will supply Adjupanrix to 12 participating European countries.
GSK delivers strong Q2 2022 sales of £6.9 billion +19% at AER, +13% at CER and Total EPS* from continuing operations** 17.5p -42% AER, -58% CER; Adjusted EPS of 34.7p +23% AER, +6% CER
Strong commercial execution across Specialty Medicines, Vaccines and General Medicines drives double-digit sales growth
ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022
Data to be presented include long-term and real-world data from portfolio of medicines
Board and Committee changes
Changes to GSK Board and Committees
Completion of GSK Share Consolidation
The consolidation of GSK shares will become effective at 8.00 a.m. tomorrow
Completion of the demerger of Haleon and share consolidation of GSK
Completion of the demerger of Haleon and share consolidation of GSK
GSK gathers global experts to discuss role of vaccines in protecting people and the planet
'Palio’ meeting to address growing threat to human health from infectious disease and its links to nature loss and climate change.
Result of General Meeting
At a General Meeting on Wednesday 6 July 2022 both resolutions set out in the Notice of General Meeting were duly passed by shareholders.